Table 1

Number of amplifications for all of the analyzed oncogenes with respect to localization and stage

CCND1MYCEGFRERBB2ZNF217
All tumors (n = 609)34.5%8.8%12.7%3.6%6.2%
(181/524)(42/473)(63/496)(18/502)(27/436)
adv.dis.a carcinomas (n = 98)30.9%10.5%7.7%1.2%5.2%
(25/81)(8/76)(6/78)(1/83)(4/76)
versus
Primary carcinomas (n = 511)36.0%8.6%13.7%4.2%6.4%
(156/433)(34/397)(57/418)(17/402)(23/360)
PsP = 0.15P = 0.66P = 0.19P = 0.33P = 1.0
Oral cavity (n = 245)30.3%10.1%11.5%3.8%9.6%
(61/201)(21/207)(24/209)(8/213)(19/197)
versus
Pharynx (n = 160)49.7%7.3%15.9%5.5%1.9%
(73/147)(9/114)(20/126)(7/127)(2/107)
versus
Larynx (n = 106)25.9%6.0%15.7%2.5%3.6%
(22/85)(4/67)(13/83)(2/79)(2/56)
PsP < 0.001P = 0.54P = 0.41P = 0.64P = 0.02
T1–2 carcinomas (n = 199)32.7%7.2%9.2%2.4%6.4%
(54/165)(11/152)(15/163)(4/167)(9/141)
versus
T3–4 carcinomas (n = 267)39.0%8.5%14.3%4.2%6.7%
(90/231)(18/211)(32/223)(9/213)(13/194)
PsP = 0.24P = 0.7P = 0.16P = 0.4P = 1.0
Stage I–III carcinomas (n = 164)23.1%7.6%10.0%3.1%5.5%
(31/134)(9/118)(13/130)(4/130)(6/109)
versus
Stage IV carcinomas (n = 300)43.1%7.8%13.4%3.6%7.1%
(112/260)(19/244)(34/254)(9/249)(16/224)
PsP < 0.001P = 1.0P = 0.41P = 1.0P = 0.65
  • a adv.dis., advanced disease. The numbers in parentheses represent number of amplifications versus number of analyzed tumors.